Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Mar 1997

Hoffman M A, Janson D, Rose E, Rai K R

Abstract excerpt

PURPOSE: To analyze initial and long-term outcomes after treatment of patients with active hairy-cell leukemia (HCL) with a single cycle of cladribine (2-CdA). PATIENTS AND METHODS: Forty-nine patients with active HCL were treated with 2-CdA by continuous intravenous infusion at 0.1 mg/kg/d for a total of 7 days at the Long Island Jewish Medical Center between September 1990 and August 1992. Here we report on all...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Follow-Up Studies

Share to Neutropenia

Share to Phenotype

Share to Recurrence

Share to Remission Induction

Source

Identifiers

PMID: 9060556
DOI: 10.1200/JCO.1997.15.3.1138

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.PMID 9060556Read ↗

Long-term follow-up after purine analogue therapy in hairy cell leukaemia.Semantic proximity Read ↗

[Hairy cell leukemia: What are the best treatment options for relapsed or refractory patients?]Semantic proximity Read ↗

Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior.Semantic proximity Read ↗

Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine.Semantic proximity Read ↗

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.Semantic proximity Read ↗

A variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients.Semantic proximity Read ↗

Chemoimmunotherapy for hairy cell leukemia.Semantic proximity Read ↗

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell LeukemiaSemantic proximity Read ↗

Molecular evaluation of clonal remission in hairy cell leukemia patients treated with 2-chlorodeoxyadenosine.Semantic proximity Read ↗

Efficacy of vemurafenib in hairy-cell leukemia.Semantic proximity Read ↗

Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.Semantic proximity Read ↗

Immunoconjugates in the management of hairy cell leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.